7:11 am Myriad Genetics publishes data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65% of physicians changed their original treatment plans for men with prostate cancer based on results
View todays social media effects on MYGN
View the latest stocks trending across Twitter. Click to view dashboard
See who Myriad is hiring next, click here to view
